Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Jeffrey S RossLaurie M GayKai WangSiraj M AliSaranya ChumsriJulia A ElvinRon BoseJo-Anne VergilioJames SuhRoman YelenskyDoron LipsonJuliann ChmieleckiStanley WaintraubBrian Leyland-JonesVincent A MillerPhilip J StephensPublished in: Cancer (2016)
Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2654-2662. © 2016 American Cancer Society.